Clear leader
14 companies value 126 bn revenue 7.2 bn margin -76.2% free cash flow -2.7 bn avg. score 0.7
MRNA holds 71.9% of the group's value, 4.0x the runner-up
| Rank | Ticker | Company | Share | Value | Revenue | Margin | FCF | 5 years | FCF/px | Yield | What it does · why it is here |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MRNA | Moderna United States · score 0.2 | 72% | 91 bn | 2.2 bn | -141.4% | -1.2 bn | -1.4% | — | Messenger RNA vaccines and therapies · The most advanced mRNA platform; high risk, pipeline in oncology | |
| 2 | BNTX | BioNTech Germany · score 3.2 | 18% | 22 bn | 3.2 bn | -39.6% | 0.3 bn | 1.4% | — | Messenger RNA vaccines and immunotherapies, from Germany · Pfizer's partner in the mRNA vaccine; a strong cash position to fund the pipeline | |
| 3 | PCVX | Vaxcyte, Inc. United States · score 0.0 | 8% | 9.5 bn | — | — | -0.9 bn | -9.4% | — | High-fidelity vaccines against bacterial diseases · California | |
| 4 | NVAX | Novavax United States · score 0.0 | 1% | 1.8 bn | 0.4 bn | -59.9% | -0.0 bn | -2.4% | — | Recombinant protein vaccines · Recombinant protein vaccine, an alternative to mRNA | |
| 5 | VALN | Valneva SE France · score 0.0 | 0% | 0.5 bn | 0.2 bn | -110.3% | -0.1 bn | -13.6% | — | Vaccines for infectious diseases, from France · France — revenue of $160m | |
| 6 | EBS | Emergent BioSolutions Inc. United States · score 2.8 | 0% | 0.3 bn | 0.7 bn | -23.8% | 0.1 bn | 26.3% | — | Life sciences for public health threat preparedness and response · Maryland — revenue of $743m | |
| 7 | ARCT | Arcturus Therapeutics Holdings Inc. United States · score 0.0 | 0% | 0.3 bn | 0.0 bn | -317.6% | -0.1 bn | -24.6% | — | Messenger RNA drugs for rare diseases · California — revenue of $29m | |
| 8 | RNAC | Cartesian Therapeutics, Inc. United States · score 0.0 | 0% | 0.2 bn | 0.0 bn | -103x | -0.1 bn | -42.7% | — | mRNA therapies for autoimmune diseases · Maryland — revenue of $1m | |
| 9 | GLSI | Greenwich LifeSciences, Inc. United States · score 0.0 | 0% | 0.2 bn | — | — | -0.0 bn | -5.6% | — | Phase III biopharma in breast cancer immunotherapy · Texas | |
| 10 | INO | INOVIO PHARMACEUTICALS, INC. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | — | -0.1 bn | -78.1% | — | DNA medicines for HPV, cancer and infectious diseases · Pennsylvania | |
| 11 | EVAX | Evaxion A/S Denmark · score 0.0 | 0% | 0.0 bn | 0.0 bn | -115.5% | -0.0 bn | -25.8% | — | AI-powered vaccine and immunotherapy discovery, from Denmark · Denmark — revenue of $7m | |
| 12 | ELTX | Elicio Therapeutics, Inc. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -92.7% | — | Clinical-stage biotech in immunotherapies for KRAS tumors · Massachusetts | |
| 13 | SVA | SINOVAC BIOTECH LTD China · score 1.2 | — | — | 0.4 bn | -51.5% | -0.6 bn | — | — | Human vaccines, from China · China — revenue of $386m | |
| 14 | GOVX | GeoVax Labs, Inc. United States · score 2.8 | — | — | 0.0 bn | — | -0.0 bn | — | — | Vaccines and immunotherapies against infectious diseases and cancer · Georgia |
Other industries in the same sector
- Sector overview
- Large-cap pharmaceuticals 9 companies
- Biotechnology 57 companies
- European pharmaceuticals 5 companies
- Lab tools and consumables 37 companies
- Health insurance and services 17 companies
- Medical devices 87 companies
- Specialty pharmaceuticals 77 companies
- Pharmaceutical distribution 7 companies
- Clinical-stage pharmaceuticals 251 companies
- Robotic surgery and advanced medtech 9 companies
- Hospitals 23 companies
- Emerging biotech 5 companies
and 22 industries more
- Molecular testing and advanced diagnostics 42 companies
- Clinical-stage biotech 200 companies
- Generics and biosimilars 10 companies
- Animal health 7 companies
- Contract research (CRO) 10 companies
- Consumer health (OTC) 4 companies
- Healthcare software 18 companies
- Rehabilitation and home care 15 companies
- Genomics and sequencing 9 companies
- Structural heart 8 companies
- Ophthalmology 12 companies
- Medical imaging and hospital equipment 16 companies
- Diagnostic labs 6 companies
- Medical and dental supply distribution 3 companies
- Diabetes monitoring 9 companies
- Pharmaceutical royalties 5 companies
- Respiratory and sleep therapy 9 companies
- Orthopedic implants 17 companies
- Dialysis 3 companies
- Telehealth and digital health 12 companies
- Dental 4 companies
- Medical and recreational cannabis 16 companies
What this is. A catalogue, not a guide. Every industry with stocks listed on the NYSE or NASDAQ, the companies contending for its leadership, what each one does according to its own annual report, and the balance sheet it filed with the SEC.
The score runs from 0 to 10 and compares each company with every other one in the almanac on cash generation, profitability, debt, dividends and consistency over the last five years. The higher it is, the better the company fares in that comparison. Curious how much each part weighs? Ask at the bottom of the page.
The score runs from 0 to 10 and compares each company with every other one in the almanac on cash generation, profitability, debt, dividends and consistency over the last five years. The higher it is, the better the company fares in that comparison. Curious how much each part weighs? Ask at the bottom of the page.